Zura Bio (NASDAQ:ZURA) Now Covered by Wedbush

Wedbush initiated coverage on shares of Zura Bio (NASDAQ:ZURA) in a research report report published on Monday, MarketBeat reports. The firm issued an outperform rating and a $15.00 target price on the stock.

Other analysts have also recently issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Chardan Capital reissued a “buy” rating and set a $10.00 price target on shares of Zura Bio in a research report on Friday, November 14th. Wall Street Zen downgraded Zura Bio from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Finally, Leerink Partners upgraded Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Zura Bio has an average rating of “Moderate Buy” and a consensus target price of $11.60.

Zura Bio Trading Up 4.3%

Zura Bio stock opened at $6.27 on Monday. The stock’s fifty day simple moving average is $5.00 and its 200-day simple moving average is $3.60. The firm has a market capitalization of $407.68 million, a P/E ratio of -9.65 and a beta of 0.21. Zura Bio has a twelve month low of $0.97 and a twelve month high of $6.88.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Sell-side analysts predict that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Investors Weigh In On Zura Bio

A number of large investors have recently made changes to their positions in the company. Allworth Financial LP bought a new stake in shares of Zura Bio in the 4th quarter valued at approximately $30,000. Scientech Research LLC acquired a new position in shares of Zura Bio during the third quarter valued at about $45,000. Forefront Wealth Partners LLC acquired a new position in Zura Bio in the 3rd quarter valued at approximately $93,000. Squarepoint Ops LLC bought a new position in Zura Bio in the third quarter worth $109,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Zura Bio during the 3rd quarter worth about $138,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.